Figure 4.

Multi-modal imaging of the effect of antiviral treatment on influenza virus-mediated inflammation. (A) Infected mice were treated with oseltamivir (OSV, 10 mg/kg bid) beginning 2 days post infection (dpi) or mock treated; Serial bioluminescence imaging of the same cohort of animals was used to detect statistically significant differences in viral load over time between mock and OSV treatment (p = 0.0085, 2-way ANOVA); (B) Multi-modal bioluminescence and positron emission tomography–computed tomography (PET/CT) imaging. [18F]-2-deoxy-2-fluoro-d-glucose (¹⁸F-FDG) was used as a probe to measure inflammation in the lungs. Representative data from uninfected and infected mice are shown; (C) Dual quantification of viral load (bioluminescent radiance) and inflammation (%-injected dose(ID)/g) in the lungs of infected or control mice. Three different Hounsfield unit thresholds were used to define lung tissue by CT from which ¹⁸F-FDG was quantified by PET. Data were collected from one control mouse, two infected mice, and two infected mice treated with OSV.